drugset / Trial / NCT04760769

Open-label Trial in Parkinson's Disease (PD)

NCT04760769

Phase 3 Completed 992 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.

Timeline

Start
2021-02-24
Primary completion
2025-12-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavapadon Small molecule 5 mg Oral
Subject Tavapadon Small molecule 15 mg Oral

Indications